XML 77 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation Expense (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense
Compensation expense related to stock-based awards was recorded as follows:
Year Ended December 31,
(in millions)202320222021
Cost of revenue$0.4 $0.4 $0.5 
Research and development11.5 8.9 7.6 
Selling, general and administrative36.4 31.6 26.3 
Total$48.3 $40.9 $34.4 
Schedule of Stock Option Activity
The following summarizes the activity under the Company’s stock option plans:
Number of
Options
Weighted Average
Exercise Price
Weighted Average Remaining Contractual Term
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding at December 31, 2022
695,588 $109.73 
Granted72,209 $276.36 
Exercised(250,192)$67.30 $52.7 
Forfeited and canceled(81,511)$250.47 
Outstanding at December 31, 2023
436,094 $135.37 3.8$43.2 
Vested, December 31, 2023
335,862 $95.35 2.4$43.1 
Vested or expected to vest, December 31, 2023
420,190 $130.18 3.6$43.2 
Schedule of Assumptions Used for Options Granted
The assumptions used in the Black-Scholes pricing model for options granted during each year, along with the weighted-average grant-date fair values, were as follows:
 Years Ended December 31,
 202320222021
Risk-free interest rate
4.3%
1.8%
0.5% - 0.6%
Expected life of options (in years)
4.2
4.2
4.2 - 4.4
Dividend yield—%—%—%
Expected stock price volatility
45.7%
42.8%
41.4% - 41.6%
Fair value per option$115.32 $93.26 $95.92 
Schedule of Restricted Stock Units
Activity for RSUs is as follows:
Number of
Shares
Weighted
Average
Fair Value
Outstanding at December 31, 2022
232,726 $249.60 
Granted149,234 $259.86 
Vested(98,373)$245.14 
Forfeited(34,393)$266.65 
Outstanding at December 31, 2023
249,194 $255.31 
Schedule of Performance Stock Units
Activity for PSUs is as follows:
Number of
Shares
Weighted
Average
Fair Value
Outstanding at December 31, 2022
180,301 $249.10 
Granted(1)
60,587 $276.36 
Vested(40,023)$217.34 
Forfeited(78,399)$272.53 
Outstanding at December 31, 2023(2)
122,466 $261.65 
(1) Includes a 7,636 share adjustment to awards granted in 2020 for the three-year performance cycle award period ended 2022, based on the actual performance achievement of 84%.
(2) Based on 111% achievement of the performance metrics, approximately 18,000 shares of Insulet were earned for awards that were granted in 2021 for the performance period ended December 31, 2023. These shares vested in February 2024.
Schedule of Estimated Fair Value of Share Purchase Under ESPP
The estimated fair value of shares purchased under the ESPP were based on the following assumptions:
 Years Ended December 31,
 202320222021
Risk-free interest rate
 5.3% - 5.4%
1.6% - 4.7%
0.04% - 0.1%
Expected term (in years)0.50.50.5
Dividend yield—%—%—%
Expected stock price volatility
29.1% - 47.0%
44.3% - 50.1%
19.4% - 31.7%